Tag: targeted therapy for NETs

Home / targeted therapy for NETs

Categories

Cabozantinib is approved by the USFDA for adults and pediatric patients 12 years of age and older with pNET and epNET

On March 26, 2025, the Food and Drug Administration sanctioned cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients aged 12 and older with previously treated, unresectable, locall...
targeted-therapy-for-nets

Scan the code